Literature DB >> 12237081

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

Jin Q Cheng1, Xiuxian Jiang, Michael Fraser, Ming Li, Han C Dan, Mei Sun, Benjamin K Tsang.   

Abstract

Although cisplatin derivatives are first-line chemotherapeutic agents for the treatment of epithelial ovarian cancer, chemoresistance remains a major hurdle to successful therapy and the molecular mechanisms involved are poorly understood. Apoptosis is the cellular underpinning of cisplatin-induced cell death, which is associated with expression of specific "death" genes and down-regulation of "survival" counterparts. The X-linked inhibitor of apoptosis proteins (Xiap), an intracellular anti-apoptotic protein, plays a key role in cell survival by modulating death signaling pathways and is a determinant of cisplatin resistance in ovarian cancer cells in vitro. This review focuses on the role of Xiap and its interactions with the phosphoinositide-3 kinase (PI3K)/Akt cell survival pathway in conferring resistance of ovarian cancer cells to chemotherapeutic agents and discusses potential therapeutic strategies in overcoming chemoresistant ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237081     DOI: 10.1016/s1368-7646(02)00003-1

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  28 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

Review 2.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

3.  Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells.

Authors:  Aliza L Leizer; Ayesha B Alvero; Han Hsuan Fu; Jennie C Holmberg; Yung-Chi Cheng; Dan-Arin Silasi; Thomas Rutherford; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2010-09-06       Impact factor: 3.886

4.  Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.

Authors:  Jian-Ping Guo; Shao-Kun Shu; Lili He; Yi-Chun Lee; Patricia A Kruk; Seija Grenman; Santo V Nicosia; Gil Mor; Michael J Schell; Domenico Coppola; Jin Q Cheng
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

5.  Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Authors:  Peter W Schlosshauer; Wei Li; Kai-Ti Lin; Joseph L-K Chan; Lu-Hai Wang
Journal:  Gynecol Oncol       Date:  2009-07-02       Impact factor: 5.482

6.  Cell fate regulation by gelsolin in human gynecologic cancers.

Authors:  Mohammad R Abedini; Pei-Wen Wang; Yu-Fang Huang; Mingju Cao; Cheng-Yang Chou; Dar-Bin Shieh; Benjamin K Tsang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

7.  MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.

Authors:  Jia Chen; Qi Wang; Fu-Qiang Yin; Wei Zhang; Lin-Hai Yan; Li Li
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

8.  Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.

Authors:  Junnai Wang; Qinglei Gao; Qiang Li
Journal:  Tumour Biol       Date:  2015-03-29

9.  Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.

Authors:  Xuemei Xie; Jangsoon Lee; Huey Liu; Troy Pearson; Alexander Y Lu; Debu Tripathy; Gayathri R Devi; Chandra Bartholomeusz; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2020-12-15       Impact factor: 6.261

10.  Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3.

Authors:  Jin Fu; Dan Chen; Bo Zhao; Zhihui Zhao; Jiahong Zhou; Yimiao Xu; Yinqiang Xin; Chang Liu; Lan Luo; Zhimin Yin
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.